Agnes Kwak1, Jamie Jacobs1, Dana Haggett1, Rachel Jimenez1, Jeffrey Peppercorn2,3. 1. Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA, 02114, USA. 2. Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA, 02114, USA. Jpeppercorn@mgh.harvard.edu. 3. MGH Cancer Survivorship Program, Massachusetts General Hospital, Harvard Medical School, Boston, USA. Jpeppercorn@mgh.harvard.edu.
Abstract
PURPOSE: Insomnia is a common issue among patients with breast cancer with a potentially devastating impact on quality of life. It can be caused or exacerbated by multiple disease and treatment-related factors. Despite the prevalence and impact of insomnia, it is rarely addressed systematically in the oncology clinic. We conducted a comprehensive review of insomnia to guide clinical care of patient's with breast cancer and insomnia. METHODS: This manuscript reviews the prevalence, etiology, emerging science and both non-pharmacologic and pharmacologic options for treatment of insomnia among patients with breast cancer. RESULTS: Multiple factors contribute to insomnia among patients with breast cancer including endocrine therapy and hotflashes, pain and discomfort from local therapy, and fear of recurrence. If we do identify insomnia, there are treatment options and strategies available to help patients. In particular, there is now a considerable body of evidence supporting the use of psychosocial interventions and behavioral treatments, such as cognitive behavioral therapy for insomnia (CBT-I), yoga, and mind-body programs. It is also important for oncology providers to be educated regarding available pharmacologic therapies and emerging data for cannabis-based therapy. CONCLUSION: This manuscript provides an up-to-date and comprehensive review of the prevalence, etiology, and treatment approaches available for insomnia for clinicians treating patients with breast cancer. We also address strategies and goals for cancer care delivery and future research.
PURPOSE:Insomnia is a common issue among patients with breast cancer with a potentially devastating impact on quality of life. It can be caused or exacerbated by multiple disease and treatment-related factors. Despite the prevalence and impact of insomnia, it is rarely addressed systematically in the oncology clinic. We conducted a comprehensive review of insomnia to guide clinical care of patient's with breast cancer and insomnia. METHODS: This manuscript reviews the prevalence, etiology, emerging science and both non-pharmacologic and pharmacologic options for treatment of insomnia among patients with breast cancer. RESULTS: Multiple factors contribute to insomnia among patients with breast cancer including endocrine therapy and hotflashes, pain and discomfort from local therapy, and fear of recurrence. If we do identify insomnia, there are treatment options and strategies available to help patients. In particular, there is now a considerable body of evidence supporting the use of psychosocial interventions and behavioral treatments, such as cognitive behavioral therapy for insomnia (CBT-I), yoga, and mind-body programs. It is also important for oncology providers to be educated regarding available pharmacologic therapies and emerging data for cannabis-based therapy. CONCLUSION: This manuscript provides an up-to-date and comprehensive review of the prevalence, etiology, and treatment approaches available for insomnia for clinicians treating patients with breast cancer. We also address strategies and goals for cancer care delivery and future research.
Entities:
Keywords:
Breast cancer; Cognitive behavioral therapy; Insomnia; Review; Survivorship
Authors: Mingxiao Yang; Kevin T Liou; Sheila N Garland; Ting Bao; Tony K W Hung; Susan Q Li; Yuelin Li; Jun J Mao Journal: NPJ Breast Cancer Date: 2021-11-30
Authors: Charlotte Grégoire; Nolwenn Marie; Corine Sombrun; Marie-Elisabeth Faymonville; Ilios Kotsou; Valérie van Nitsen; Sybille de Ribaucourt; Guy Jerusalem; Steven Laureys; Audrey Vanhaudenhuyse; Olivia Gosseries Journal: Front Psychol Date: 2022-02-10
Authors: Thomas Schulte; Dirk Hofmeister; Anja Mehnert-Theuerkauf; Tim Hartung; Andreas Hinz Journal: Support Care Cancer Date: 2021-05-29 Impact factor: 3.603